Answers are grounded in this paper and cite their sources.
Proteomic analysis of blood plasma is a promising tool for cancer screening. A method for screening a panel of 100 clinically significant plasma proteins using targeted mass spectrometry based on multiple reaction monitoring (MRM MS) was developed. Quantitative MRM MS analysis of plasma samples from healthy donors (N = 52) and patients with hematologic malignancies, multiple myeloma (MM; N = 35) and diffuse large B-cell lymphoma (DL; N = 30), was performed, and 15 proteins whose expression was significantly altered in both tumor types were identified. Using logistic regression with ElasticNet regularization, compact diagnostic panels were generated: one consisting of four proteins (BCHE, B2M, ALB, IGHM) for tumor detection (MM/DL vs. control; AUC = 0.97) and one consisting of three proteins (IGHM, VTN, IGKV4-1) for differential diagnosis of MM and DL (AUC = 0.96). The obtained results confirm the effectiveness of the multiplex MRM MS approach for the quantitative analysis of protein biomarkers. Further research and validation on larger samples are required to evaluate the clinical significance and potential for implementing the developed method in laboratory diagnostics.
No takes yet. Share an insight, caveat, or question.
Kononikhin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: